The clinical role of procalcitonin in hematopoietic SCT
The clinical role of procalcitonin in hematopoietic SCT
复制标题
DOI：
10.1038/bmt.2012.18
复制
发表时间：
2012-10-01
影响因子：
4.8
通讯作者：
Kurokawa, M.
中科院分区：
文献类型：
--
作者：
Koya, J.;Nannya, Y.;Kurokawa, M.
造血干细胞移植（HSCT）后的感染性疾病是TRM的主要原因。需要更有价值的标志物来区分感染性疾病和非感染性并发症。在连续28例接受HSCT的患者的整个临床过程中定期测量降钙素原（PCT）和C反应蛋白（CRP）。对103例发热病例的诊断进行了分析。全身性细菌或真菌感染患者发热第一天的PCT和CRP水平显著升高（P = 2 ng/mL），作为移植后预测因子，与总体生存率下降独立相关（校正风险比6.42，P = 0.035）。PCT可为鉴别细菌或真菌感染与其他原因以及预测HSCT后患者预后提供额外信息。
Infectious disease following hematopoietic SCT (HSCT) is a major cause of TRM. The more valuable markers to distinguish infections disease from non-infectious complications are needed. Procalcitonin (PCT) and C-reactive protein (CRP) were measured periodically throughout the clinical course of consecutive 28 patients who underwent HSCT. The diagnoses of 103 febrile episodes were analyzed. PCT and CRP level on the first day of fever significantly increased in systemic bacterial or fungal infection (P = 2 ng/mL was independently associated with worse overall survival as post-transplant predictors (adjusted hazard ratio 6.42, P = 0.035). PCT provide additional information for discrimination between bacterial or fungal infection and other causes and predicting the patient's prognosis after HSCT.